Retrospective Analysis of Dabrafenib +/- Trametinib Compassionate Use Experience in Spain

• Status: Completed
• Trial end date: 2016-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to analyze whether Dabrafenib +/- Trametinib are effective in overall survival, response rates and toxicity in both programs.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Grupo Español Multidisciplinar de Melanoma
• Collaborator: GlaxoSmithKline
• Treatments: Dabrafenib; Trametinib

Criteria

Inclusion Criteria:

• Patients who have received at least one dose of dabrafenib or combination with trametinib as part of a compassionate use for the treatment of metastatic melanoma, with deadline the start of treatment the April 30, 2014.

Exclusion Criteria:

• Patients with a history not available.